143- van der Heijde D, van der Linden S, Dougados M, Bellamy N, Russell AS, Edmonds
J. Ankylosing spondylitis: plenary discussion and results of voting on selection of domains and
some specifi c instruments. J Rheumatol. 1999;26(4):1003–5 [Review]. - Ward MM. Health-related quality of life in ankylosing spondylitis: a survey of 175 patients.
Arthritis Care Res. 1999;12(4):247–55 [Research Support, Non-U.S. Gov’t]. - Verstappen SM, Jacobs JW, van der Heijde DM, van der Linden S, Verhoef CM, Bijlsma JW,
et al. Utility and direct costs: ankylosing spondylitis compared with rheumatoid arthritis. Ann
Rheum Dis. 2007;66(6):727–31. - Jones SD, Koh WH, Steiner A, Garrett SL, Calin A. Fatigue in ankylosing spondylitis: its
prevalence and relationship to disease activity, sleep, and other factors. J Rheumatol.
1996;23(3):487–90 [Research Support, Non-U.S. Gov’t]. - van Tubergen A, Coenen J, Landewe R, Spoorenberg A, Chorus A, Boonen A, et al. Assessment
of fatigue in patients with ankylosing spondylitis: a psychometric analysis. Arthritis Rheum.
2002;47(1):8–16. - Revicki DA, Rentz AM, Luo MP, Wong RL. Psychometric characteristics of the short form 36
health survey and functional assessment of chronic illness therapy-fatigue subscale for patients
with ankylosing spondylitis. Health Qual Life Outcomes. 2011;9:36 [Research Support, Non- -
U.S. Gov’t Validation Studies]. - Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to
defi ning disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activ-
ity index. J Rheumatol. 1994;21(12):2286–91 [Comparative Study Research Support,
Non-U.S. Gov't]. - Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing
spondylitis with infl iximab: a randomised controlled multicentre trial. Lancet.
2002;359(9313):1187–93 [Clinical Trial Multicenter Study Randomized Controlled Trial
Research Support, Non-U.S. Gov’t]. - Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, et al. Successful treatment of
active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody
infl iximab. Arthritis Rheum. 2000;43(6):1346–52. - Cohen JD, Cunin P, Farrenq V, Oniankitan O, Carton L, Chevalier X, et al. Estimation of the
bath ankylosing spondylitis disease activity index cutoff for perceived symptom relief in
patients with spondyloarthropathies. J Rheumatol. 2006;33(1):79–81. - Pavy S, Brophy S, Calin A. Establishment of the minimum clinically important difference for
the bath ankylosing spondylitis indices: a prospective study. J Rheumatol. 2005;32(1):80–5
[Research Support, Non-U.S. Gov’t]. - Machado P, Landewe RB, Braun J, Baraliakos X, Hermann KG, Hsu B, et al. MRI infl ammation
and its relation with measures of clinical disease activity and different treatment responses in
patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor. Ann Rheum
Dis. 2012;71(12):2002–5 [Randomized Controlled Trial Research Support, Non-U.S. Gov’t]. - Sieper J, Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, et al. Persistent reduction
of spinal infl ammation as assessed by magnetic resonance imaging in patients with ankylosing
spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infl iximab.
Rheumatology. 2005;44(12):1525–30. - Maksymowych WP, Salonen D, Inman RD, Rahman P, Lambert RG. Low-dose infl iximab (3
mg/kg) signifi cantly reduces spinal infl ammation on magnetic resonance imaging in patients
with ankylosing spondylitis: a randomized placebo-controlled study. J Rheumatol.
2010;37(8):1728–34 [Randomized Controlled Trial Research Support, Non-U.S. Gov’t]. - Kiltz U, Baraliakos X, Karakostas P, Igelmann M, Kalthoff L, Klink C, et al. The degree of
spinal infl ammation is similar in patients with axial spondyloarthritis who report high or low
levels of disease activity: a cohort study. Ann Rheum Dis. 2012;71(7):1207–11 [Comparative
Study Research Support, Non-U.S. Gov’t]. - Fagerli KM, Lie E, van der Heijde D, Heiberg MS, Kaufmann C, Rodevand E, et al. Selecting
patients with ankylosing spondylitis for TNF inhibitor therapy: comparison of ASDAS and
BASDAI eligibility criteria. Rheumatology. 2012;51(8):1479–83.
5 PROMs for Spondyloarthritis